In the latest trading session,, 0.56 million Y-Mabs Therapeutics Inc (NASDAQ:YMAB) shares changed hands as the company’s beta touched 0.75. With the company’s most recent per share price at $13.97 changed hands at -$3.24 or -18.83% at last look, the market valuation stands at $612.86M. YMAB’s current price is a discount, trading about -49.61% off its 52-week high of $20.90. The share price had its 52-week low at $4.60, which suggests the last value was 67.07% up since then. When we look at Y-Mabs Therapeutics Inc’s average trading volume, we note the 3-month average coming to 366.14K.
Y-Mabs Therapeutics Inc (NASDAQ:YMAB) trade information
Instantly YMAB was in red as seen in intraday trades today. With action -15.28%, the performance over the past five days has been red. The drop to weekly highs of 17.78 subtracted -18.83% to the stock’s daily price. The company’s shares are showing year-to-date upside of 104.84%, with the 5-day performance at -15.28% in the red. However, in the 30-day time frame, Y-Mabs Therapeutics Inc (NASDAQ:YMAB) is -0.71% down.
Y-Mabs Therapeutics Inc (YMAB) estimates and forecasts
Data shows that the Y-Mabs Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 142.96% over the past 6 months, a 12.24% in annual growth rate that is considerably lower than the industry average of 13.20%. Year-over-year growth is forecast to reach 14.50% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 19.93M. 3 analysts are of the opinion that Y-Mabs Therapeutics Inc’s revenue for the current quarter will be 23.59M. The company’s revenue for the corresponding quarters a year ago was 20.25M and 20.75M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -1.60%. The estimates for the next quarter sales put growth at 13.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 20.06%. The 2024 estimates are for Y-Mabs Therapeutics Inc earnings to increase by 6.12%.
